Who is John M. Dineen and why was he appointed to the board?

John M. Dineen is a seasoned executive with extensive leadership experience, most notably as President and CEO of GE Healthcare and GE Transportation. He was appointed to the Lam Research Corporation board to bring his considerable operational and strategic expertise to the company, enhancing the board's overall capabilities.

What is the significance of Mr. Dineen joining the Audit Committee?

Mr. Dineen's upcoming role on the Audit Committee, starting November 7, 2023, suggests the board values his financial oversight and governance experience. His background, including his audit and finance committee roles at Cognizant, indicates he is well-suited to contribute to the committee's critical functions.

Will Mr. Dineen's appointment affect director compensation?

No, the filing states that Mr. Dineen will receive compensation for his service as a director consistent with Lam Research's current policies for non-employee directors. His appointment does not indicate a change in the standard compensation structure for directors.

Are there any potential conflicts of interest with Mr. Dineen's appointment?

Based on the filing, there are no disclosed arrangements or understandings between Mr. Dineen and any other individuals regarding his appointment. He also does not have any family relationships with current directors or officers, nor does he have a direct or indirect material interest in any transaction requiring reporting under Regulation S-K.

LRCX 8-K: Leadership Changes

Summary

Lam Research Corporation (LRCX) announced a significant board refreshment with the appointment of John M. Dineen as a new director, effective August 24, 2023. Mr. Dineen brings extensive leadership experience from his tenure at General Electric, including serving as President and CEO of GE Healthcare and GE Transportation, and his recent role as an Operating Advisor at Clayton, Dubilier & Rice. His appointment expands the board to eleven members and he will join the Audit Committee in November 2023. Mr. Dineen's diverse background in global operations, technology, and previous board experience with publicly traded and private companies, such as Cognizant Technology Solutions and Syneos Health, is expected to provide valuable strategic insights. Investors can view this as a move to enhance board expertise and governance. Mr. Dineen's compensation will align with the company's standard director compensation policies, and he will be subject to the company's standard indemnification agreement.

Key Highlights

1John M. Dineen appointed as a new director to the Board of Directors, effective August 24, 2023.
2Mr. Dineen's appointment increases the board size to eleven members.
3He has a strong background with significant leadership roles at General Electric, including President and CEO of GE Healthcare and GE Transportation.
4Mr. Dineen will join the Audit Committee of the Board, effective November 7, 2023.
5He brings experience from private equity as an Operating Advisor at Clayton, Dubilier & Rice.
6His previous board experience includes roles at Cognizant Technology Solutions Corporation and Syneos Health, Inc.

LAM RESEARCH CORP 8-K Report, Executive Changes (Aug 24, 2023)

Summary

Key Highlights

Frequently Asked Questions